Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 11, Novembre 2007
Page(s) 957 - 960
Section M/S revues
DOI https://doi.org/10.1051/medsci/20072311957
Publié en ligne 15 novembre 2007
  1. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282 : 1264–9 [Google Scholar]
  2. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005; 28 : 137–52. [Google Scholar]
  3. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338 : 1128–37. [Google Scholar]
  4. Bérard A, Oraichi D. Development of a surveillance and signal detection system to monitor medication exposure during pregnancy and lactation. Pharmacoepidemiol Drug Saf 2004; 13 : S1-334 (253). [Google Scholar]
  5. US Department of Health and Human Services. Mental health : a report of the surgeon general. Executive summary of 1999. http://www.surgeongeneral.gov/library/mentalhealth/pdfs/c4.pdf. [Google Scholar]
  6. International Clearinghouse for Birth Defects Monitoring Systems, Annual report Rome : ICBDMS, 2003. [Google Scholar]
  7. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy : fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26 : 44–8. [Google Scholar]
  8. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. Br J Obstet Gynecol 2007; 114 : 1055–64. [Google Scholar]
  9. Health Canada. Health Canada endorsed important safety information on Paxil (paroxetine), 2005. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2005/paxil_3_hpc-cps_f.html [Google Scholar]
  10. US Food and Drug Administration. FDA Public Health Advisory Paroxetine of 2005. http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm [Google Scholar]
  11. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354 : 579–87. [Google Scholar]
  12. Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants : the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80 : 18–27. [Google Scholar]
  13. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63 : 898–906. [Google Scholar]
  14. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295 : 499–507. [Google Scholar]
  15. Lou HC, Hansen D, Nordentoft M, et al. Prenatal stressors of human life affect fetal brain development. Dev Med Child Neurol 1994; 36 : 826–32. [Google Scholar]
  16. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995; 17 : 165–71. [Google Scholar]
  17. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995; 15 : 778–80. [Google Scholar]
  18. Buist A. Perinatal depression : assessment and management. Aust Fam Physician 2006; 35 : 670–3. [Google Scholar]
  19. Beck CT. The effects of postpartum depression on maternal-infant interaction : a meta-analysis. Nurs Res 1995; 44 : 298–304. [Google Scholar]
  20. Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43 : 225–37. [Google Scholar]
  21. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148 : 1234–6. [Google Scholar]
  22. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56 : 17–20. [Google Scholar]
  23. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153 : 1132–7. [Google Scholar]
  24. Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 1996; 4 : 117–25. [Google Scholar]
  25. Ramos E, St-André M, Rey E, Bérard A. Risk of congenital malformations associated with duration of exposure to antidepressants during the gestational period. Br J Psychiatry 2007 (accepté pour publication). [Google Scholar]
  26. Blier P. Pregnancy, depression, antidepressants and breast-feeding. J Psychiatry Neurosci 2006; 31 : 226–8. [Google Scholar]
  27. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161 : 22–9. [Google Scholar]
  28. Rubinow DR. Antidepressant treatment during pregnancy : between Scylla and Charybdis. Am J Psychiatry 2006; 163 : 954–6. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.